Download RESEARCH PRESENTATION Cancer drug reimbursement

yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Harm reduction wikipedia , lookup

Medical research wikipedia , lookup

Drug discovery wikipedia , lookup

Prescription costs wikipedia , lookup

Cancer drug reimbursement decisions in Canada
Dr. Wiesława D. Wranik
Decyzje w sprawie refundacji leków onkologicznych w Kanadzie
December 15th, 2016
3:00 to 5:00 p.m.
Location 418 A (Gmach Główny Uniwersytetu Ekonomicznego w Poznaniu)
Canada is a federal state with a publicly funded health care system. Drugs are funded by
governments only in selected circumstances, for example when they are oncological. The
funding decision is made by regional governments, but the review of evidence to support the
decisions is a national process undertaken through the pan-Canadian Oncology Drug Review
(pCODR). This presentation will:
1. Describe the pCODR process and compare it to a previous regional process;
2. Explore the preferences of the pCODR committee as identified in the publicly available
recommendation reports;
3. Explore the impact of patient values on recommendations made by pCODR;
The purpose of the presentation is to provide an overview of a research program currently
underway in Canada, and to explore potential research collaborations with researchers in
Poland and about the Polish drug review process.
Dr. Wieslawa D. Wranik is an Associate Professor and the Associate Dean Research at the
Faculty of Management at Dalhousie University in Halifax, Nova Scotia. She is appointed to the
School of Public Administration and cross-appointed with the Department of Community Health
and Epidemiology. Her research focuses on the application of economics to health policy
questions. This includes leading a research program to investigate the use of economic
evaluations in drug reimbursement, and active participation in drug review processes as Lead of
the Economic Guidance Panel of the pCODR. Details about the research program can be found
at and about the pCODR can be found at .